Overview
- Editors:
-
-
Herman Friedman
-
University of South Florida, Tampa, USA
-
Thomas W. Klein
-
University of South Florida, Tampa, USA
-
Hideyo Yamaguchi
-
Teikyo University School of Medicine, Tokyo, Japan
Access this book
Other ways to access
Table of contents (34 chapters)
-
- Masaaki Ishizuka, Fuminori Abe, Shigeru Abe, Katsuhisa Uchida, Tatsuo Ikeda, Noriko Ito et al.
Pages 193-200
-
- Yutaro Kaneko, Goro Chihara
Pages 201-215
-
-
-
- Yoshimasa Yamamoto, Katsuhisa Uchida, Thomas W. Klein, Herman Friedman, Hideyo Yamaguchi
Pages 231-241
-
- Page S. Morahan, Angelo J. Pinto
Pages 243-251
-
- Ichiro Azuma, Chiaki Ishihara, Joji Iida, Yung Choon Yoo, Kumiko Yoshimatsu, Jiro Arikawa
Pages 253-263
-
- H. Masutani, H. Nakamura, Y. Ueda, Y. Kitaoka, T. Kawabe, S. Iwata et al.
Pages 265-274
-
- K. Noel Masihi, Beate Rohde-Schulz, Karel Masek, Bram Palache
Pages 275-286
-
-
-
- Yasuhiro Mizoguchi, Yasuhiro Komatsu, Yasufumi Ohkura
Pages 309-317
-
- Susumu Ikehara, Hideki Kawamura, Yasuhiro Komatsu, Haruki Yamada, Hiroko Hisha, Ryoji Yasumizu et al.
Pages 319-330
-
- Hiroshi Sakagami, Kunio Konno, Yutaka Kawazoe, Patrick Lai, Meihan Nonoyama
Pages 331-335
-
-
Back Matter
Pages 341-347
About this book
This volume is based on the Proceedings of the International Conference on "Microbial Infections: Role of Biological Response Modifiers" held in Tampa, FL, May 29-31, 1991. The major purpose of this conference was to bring together in one forum prominent investigators from around the world studying a variety of microbial pathogens, including bacteria, viruses, and fungi, and the effects of biological response modifiers (BRM) on the immune response to these microorganisms. BRM have been widely utilized in the area of antitumor resistance and include not only experimental tumor cell vaccines, but also biologically active substances such as cytokines, i. e. , interferons, tumor necrosis factor, and interleukins, as well as products from bacteria which influence host resistance mechanisms. It is the belief of the organizers of this Conference that it was very timely to discuss in detail BRMs as they impact on microbial infections per se. It is now widely accepted that immunocompromised individuals, including those exposed to immunosuppressive substances such as antimetabolites used for chemothera py of malignancies, or infectious agents, such as the human immunodeficiency virus and other viruses which depress the immune response and, in turn, affect a host so as to become highly susceptible to opportunistic microorganisms, benefit from BRM stimulation of their immune system. A wide variety of immunomodulators are now being studied in terms of treating infectious diseases, as well as malignancy and autoimmune diseases.